These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32472970)

  • 1. Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient.
    Pai V; Abu-Arja R; Auletta JJ; Rangarajan HG
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28298. PubMed ID: 32472970
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
    Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
    Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
    Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective use of tocilizumab for the treatment of steroid-refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin-6.
    Kolb M; Bhatia M; Madina GG; Satwani P
    Pediatr Blood Cancer; 2015 Feb; 62(2):362-363. PubMed ID: 25212196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease.
    Isshiki K; Kamiya T; Endo A; Okamoto K; Osumi T; Kawai T; Arai K; Tomizawa D; Ohtsuka K; Nagahori M; Imai K; Kato M; Kanegane H
    Int J Hematol; 2022 Apr; 115(4):590-594. PubMed ID: 34724153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
    Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
    Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
    Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
    Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with steroids of upper gastrointestinal acute graft vs. host disease after hematopoietic stem cell transplantation.
    Nishi T; Okazaki K; Fujii S; Uchida K; Uose S; Nakase H; Ohana M; Nishihara T; Chiba T
    Endoscopy; 2001 Nov; 33(11):985-7. PubMed ID: 11668409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.
    Ganetsky A; Frey NV; Hexner EO; Loren AW; Gill SI; Luger SM; Mangan JK; Martin ME; Babushok DV; Drobyski WR; Smith J; Timlin C; Freyer CW; Stadtmauer EA; Porter DL
    Bone Marrow Transplant; 2019 Feb; 54(2):212-217. PubMed ID: 29795429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review.
    Fukuta T; Muramatsu H; Yamashita D; Sajiki D; Maemura R; Tsumura Y; Yamamori A; Imaya M; Wakamatsu M; Nishikawa E; Narita K; Kataoka S; Taniguchi R; Narita A; Nishio N; Takahashi Y
    Int J Hematol; 2023 Sep; 118(3):411-417. PubMed ID: 37074509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
    Saraf SL; Oh AL; Patel PR; Jalundhwala Y; Sweiss K; Koshy M; Campbell-Lee S; Gowhari M; Hassan J; Peace D; Quigley JG; Khan I; Molokie RE; Hsu LL; Mahmud N; Levinson DJ; Pickard AS; Garcia JG; Gordeuk VR; Rondelli D
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):441-8. PubMed ID: 26348889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vedolizumab for treatment of steroid-refractory intestinal acute graft-versus-host disease: two cases report and literature review].
    Gao SC; Feng YM; Gao L; Kong PY; Zhu LD; Liu J; Wang L; Liu HF; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1046-1049. PubMed ID: 36709113
    [No Abstract]   [Full Text] [Related]  

  • 13. Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute graft-versus-host disease: a Chinese single-center experience in a group of 64 patients.
    Tao T; Ma X; Yang J; Zou JY; Ji SM; Tan YS; Gong W; Du F; Xu J; Ye CM; Tang XW; Wu DP; Xue SL
    Blood Cancer J; 2015 Apr; 5(4):e308. PubMed ID: 25885428
    [No Abstract]   [Full Text] [Related]  

  • 14. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-
    Drobyski WR; Szabo A; Zhu F; Keever-Taylor C; Hebert KM; Dunn R; Yim S; Johnson B; D'Souza A; Eapen M; Fenske TS; Hari P; Hamadani M; Horowitz MM; Rizzo JD; Saber W; Shah N; Shaw B; Pasquini M
    Haematologica; 2018 Apr; 103(4):717-727. PubMed ID: 29351985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.
    Meunier M; Bulabois CE; Thiebaut-Bertrand A; Itzykson R; Carre M; Carras S; Garban F; Cahn JY
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1451-4. PubMed ID: 24910381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.
    McDuffee E; Aue G; Cook L; Ramos-Delgado C; Shalabi R; Worthy T; Vo P; Childs RW
    Bone Marrow Transplant; 2017 May; 52(5):759-761. PubMed ID: 28067871
    [No Abstract]   [Full Text] [Related]  

  • 17. Intra-arterial methylprednisolone for severe steroid refractory gastrointestinal graft-versus-host disease.
    Bhuller KS; Heran MK; Wu JK; Rassekh SR
    Pediatr Blood Cancer; 2014 Dec; 61(12):2321-3. PubMed ID: 25053422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Intravenous Posaconazole in Hematopoietic Stem Cell Transplant Patients.
    Strommen A; Hurst AL; Curtis D; Abzug MJ
    J Pediatr Hematol Oncol; 2018 May; 40(4):e203-e206. PubMed ID: 29309375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab for pediatric patients with gastrointestinal acute graft-versus-host-disease.
    Aldouby Bier G; Zaidman I; Dinur Schejter Y; NaserEddin A; Stepensky P; Even-Or E
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30061. PubMed ID: 36326084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatologic complications in pediatric patients after hematopoietic stem cell transplantation for sickle cell disease.
    Dignum T; Burroughs L; Mallhi K; Brandling-Bennett HA
    Pediatr Dermatol; 2024; 41(1):61-65. PubMed ID: 37965881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.